quadraScope Ventures | Investing in healthy lifespans

Investing
in healthy
lifespans

quadraScope invests in healthcare companies developing pharmaceuticals, diagnostics, software, equipment and devices enabling biological age reversal, disease treatment, prevention and longevity.

Hallmarks of aging

Biogerontology is the new science that aims to extend human healthspan by addressing the biological basis of aging. It revolves around the concept of the Hallmarks of Aging, a framework introduced in 2013 by López-Otín et al. and further expanded in the paper Hallmarks of Aging: An Expanding Universe in 2023. The hallmarks of aging are shown below.

Genomic instability

Accumulation of DNA mutations due to failure of DNA repair mechanisms.

Telomere attrition

Shortening of the protective caps at the ends of chromosomes, leading to DNA damage and senescence.

Epigenetic alterations

Modifications in the way DNA is stored, read, and expressed, without altering the gene sequence.

Cellular senescence

Senescent cells are no loner able to divide, cannot die, and contribute to inflammation.

Mitochondrial dysfunction

Mitochondria, the energy-producing structures within cells, become leaky and inefficient.

Stem cell exhaustion

A decline in the number and function of stem cells, which are responsible for maintaining and repairing tissues.

Deregulated nutrient-sensing

Disruption of the mechanisms that control metabolism, utilization of nutrients, and energy balance.

Loss of proteostasis

Failure to maintain protein quality and function, leading to the accumulation of damaged proteins.

Disabled macroautophagy

Decreased ability to break down and recycle damaged or unnecessary cellular parts.

Altered intercellular communication

Communication systems between cells become unstable and cells lose the ability to work together effectively.

Chronic inflammation

The immune system stays persistently active even when there is no infection to fight or injury to repair.

Dysbiosis

Unbalanced populations of microorganisms that live in the human body.

Portfolio

Rejuvenation of the immune system using the secretome of immune system stem cells
Learn more

Nanomachines (NaNots) that capture and remove harmful proteins from the bloodstream
Learn more

Cellular rejuvenation with initial focus on facial rejuvenation and enhancement of immune cells for CAR-T therapy
Learn more

Fix receding gums, facial aging, incontinence, and more via novel regenerative collagen
Learn more

Personalized medicine and drug discovery via a Machine Learning platform that models an individual’s state and history of health
Learn more

DNA fault detection and error correction platform to diagnose, prevent, and treat diseases associated with the loss of genetic information
Learn more

Treat pulmonary fibrosis and type II diabetes by boosting the immune system’s capacity to remove specific senescent cells
Learn more

Cholesterol degradation platform to reverse atherosclerosis and fatty liver disease
Learn more

Treating neurodegeneration, renal diseases, and other conditions by enhancing mitochondrial health through mitophagy
Learn more

Personalized healthcare platform using human organoids subjected to accelerated aging
Learn more

Franchise of clinics specializing in personalized rejuvenation treatments and offshore clinical trials
Learn more

Gene therapy using Klotho and other molecules to treat aging and Alzheimer’s disease
Learn more

Platform for discovering and repurposing longevity drugs based on the precise understanding of their mechanisms of action Learn more

Aubrey de Grey, PhD

President & CSO, Longevity Escape Velocity Foundation

30-second video

Team

We are a women-led team with a strong track record of taking new ventures from inception to profitable exits, including a 12x exit, and deep understanding of the emerging longevity science and market.

Core team

Fiona Miller

Managing Partner

José Navarro-Betancourt, MD, PhD

Scientific Director

Scientific advisory board

Nir Barzilai, MD

Venture Partner

Aubrey de Grey, PhD

Venture Partner

Carmela Abraham, PhD

Venture Partner

Robert Cargill, PhD

Venture Partner

Diane Seimetz, PhD

Venture Partner

Reason

Venture Partner

Nikola Markov, PhD

Venture Partner

Business advisory board

Miri Polachek

Venture Partner

Nico Helling

Venture Partner

Frank Wellens

Venture Partner

Daniel Fylstra

Venture Partner

Lan Clark

Venture Partner

José Cordeiro, PhD

Venture Partner

The quadraScope team is focused on the right sector, with the right team to select and vet investment opportunities. The rejuvenation industry is an emerging next wave of biotech technologies that has seen a recent surge in funding while engaging the top scientific talent.

Hans Keirstead, PhD

Chairman, Immunis

We chose to partner with quadraScope because of the strategic alignment of our visions, namely the importance of investment in programs that extend life-span and health-span while at the same time applying the same science to treat diseases that have no treatment.

Menachem Abraham

Co-founder & CEO, Klogenix

quadraScope is tapping the fast-emerging rejuvenation market with an abundance of research ready to be commercialized. With their strategic locations in Boston and Tel-Aviv they are poised to leverage the high concentration of biotech academia, industry and talent pool.

Reason

CEO, Repair Biotechnologies

I am privileged to serve on quadraScope’s scientific advisory board. I do so because Fiona and her colleagues have made, and continue to make, outstanding choices of investments in the longevity space. quadraScope’s portfolio consists of a wisely diversified set of companies at a variety of stages of preclinical and clinical development, each possessing unique and immensely exciting technology that promises to contribute substantially to medical progress.

Aubrey de Grey, PhD

President & CSO, Longevity Escape Velocity Foundation

quadraScope, our first investor, has encouraged the formation of rejuvenation clinics and has been active in defining the treatment protocols as a strategic pillar alongside clinical trials.

Petr Sramek

CEO, Healthy Longevity Clinic

Turn Bio receives positive feedback following an FDA INTERACT meeting to advance epigenetic reprogramming for skin rejuvenation into clinical trials

FDA endorses Loyal’s veterinary clinical study to test drugs aiming to extend the lifespan and healthspan of companion dogs

quadraScope to present at the Longevity Summit Dublin

quadraScope to present at the Foresight Institute Longevity Frontiers Workshop

Top scientists and biotech industry leaders create the Biomarkers of Aging Consortium to establish reliable biomarkers of aging for the identification and validation of longevity interventions.

Our portfolio company, Immunis, announced the first-in-human injection of its stem cell secretome product to treat age and disease-related immune decline

Nanoparticles to treat aging and age-related diseases – interview with Louis Hawthorne

The NIH awards the SenNet Consortium $190M to support senescent cell research. The capital comes from a $660M strategic fund reserved for projects with the potential to transform biomedical research.

Investing in healthylifespans

Genomic instability

Telomere attrition

Epigenetic alterations

Cellular senescence

Mitochondrial dysfunction

Stem cell exhaustion

Deregulated nutrient-sensing

Loss of proteostasis

Disabled macroautophagy

Altered intercellular communication

Chronic inflammation

Dysbiosis

Portfolio

Aubrey de Grey, PhD

Core team

Fiona Miller

Managing Partner

José Navarro-Betancourt, MD, PhD

Scientific Director

Scientific advisory board

Nir Barzilai, MD

Venture Partner

Aubrey de Grey, PhD

Venture Partner

Carmela Abraham, PhD

Venture Partner

Robert Cargill, PhD

Venture Partner

Diane Seimetz, PhD

Venture Partner

Reason

Venture Partner

Nikola Markov, PhD

Venture Partner

Business advisory board

Miri Polachek

Venture Partner

Nico Helling

Venture Partner

Frank Wellens

Venture Partner

Daniel Fylstra

Venture Partner

Lan Clark

Venture Partner

José Cordeiro, PhD

Venture Partner

Hans Keirstead, PhD

Chairman, Immunis

Menachem Abraham

Co-founder & CEO, Klogenix

Reason

CEO, Repair Biotechnologies

Aubrey de Grey, PhD

President & CSO, Longevity Escape Velocity Foundation

Petr Sramek

CEO, Healthy Longevity Clinic

News and events

Contact us

Investing
in healthy
lifespans

Jose Navarro-Betancourt

Scientific Director at quadraScope

Jose Navarro-Betancourt

Scientific Director at quadraScope

Cambridge, Massachusetts

Overview

Work Experience

quadraScope

Scientific Director

2022 - Current

Education

McGill University

Doctor of Philosophy - PhD

2016 - 2021

Universidad Panamericana

Doctor of Medicine - MD

2010 - 2016

Relevant Websites